Floatz logo

154 assets in Colon Carcinoma

Therapeutic assets addressing Colon Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Osimertinib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Colon Carcinoma
The Netherlands Cancer InstituteP2CCC (53)
Sapanisertib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Toripalimab
Colon Carcinoma
Emory UniversityP2CCC (53)
Trametinib
Colon Carcinoma
City of Hope Medical CenterP2CCC (53)
Trastuzumab Emtansine
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Tucatinib
Colon Carcinoma
Academic and Community Cancer Research UnitedP2CCC (53)
Ulixertinib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Vismodegib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Zanidatamab
Colon Carcinoma
Emory UniversityP2CCC (53)
Adavosertib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (52)
Entinostat
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (52)
Fludarabine
Colon Carcinoma
Essen BiotechP1/2CCC (52)
Fruquintinib
Colon Carcinoma
Korea University Anam HospitalP2CCC (52)
Nuvastatic
Colon Carcinoma
Natureceuticals Sdn BhdP3CCC (52)
Regorafenib
Colon Carcinoma
City of Hope Medical CenterP2CCC (52)
Tas-102
Colon Carcinoma
Rutgers, The State University of New JerseyP2CCC (52)
Xljdod Compound Granule
Colon Carcinoma
Jiangsu Famous Medical Technology Co., Ltd.P3CCC (52)
Ctx-009
Colon Carcinoma
Compass TherapeuticsP2CCC (51)
Rivoceranib
Colon Carcinoma
Fudan UniversityP2CCC (51)
Taselisib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Copanlisib
Colon Carcinoma
National Cancer Institute (NCI)P2CCC (49)
Anti-Clever-1 Monoclonal Antibody Fp-1305
Colon Carcinoma
Faron Pharmaceuticals LtdP1/2CCC (48)
Bms-986504
Colon Carcinoma
Northwestern UniversityP1/2CCC (48)
Cabozantinib
Colon Carcinoma
University of Colorado, DenverP2CCC (48)
Chlorpromazinum
Colon Carcinoma
Sadat City UniversityP1/2CCC (48)
Dostarlimab
Colon Carcinoma
Universitaire Ziekenhuizen KU LeuvenP2CCC (48)
Envafolimab
Colon Carcinoma
Sun Yat-sen UniversityP2CCC (48)
Fianlimab
Colon Carcinoma
John Strickler, M.D.P2CCC (48)
Gevokizumab
Colon Carcinoma
NSABP Foundation IncP2CCC (48)
Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific
Colon Carcinoma
M.D. Anderson Cancer CenterP2CCC (48)
Indocyanine Green
Colon Carcinoma
Tanta UniversityP2CCC (48)
Iodized Ethyl Esters Of Poppyseed Fatty Acids
Colon Carcinoma
City of Hope Medical CenterP2CCC (48)
Iron(Ii) Sulphate (1:1), Heptahydrate
Colon Carcinoma
Korea University Guro HospitalP2CCC (48)
Iron Isomaltoside
Colon Carcinoma
Korea University Guro HospitalP2CCC (48)
Ivonescimab
Colon Carcinoma
Sun Yat-sen UniversityP2CCC (48)
lt-002 (lactobacillus reuteri atg-f4
Colon Carcinoma
Chungnam National University HospitalP2CCC (48)
Mesalamine
Colon Carcinoma
Ann-Sofie BackmanP2CCC (48)
Raltitrexed
Colon Carcinoma
Fudan UniversityP2CCC (48)
Rimegepant
Colon Carcinoma
Fudan UniversityP2CCC (48)
Serplulimab
Colon Carcinoma
Ruijin HospitalP2CCC (48)
SX682
Colon Carcinoma
M.D. Anderson Cancer CenterP1/2CCC (48)
Tegafur Gimeracil Oteracil Potassium
Colon Carcinoma
Guangzhou University of Traditional Chinese MedicineP2CCC (48)
Temuterkib
Colon Carcinoma
M.D. Anderson Cancer CenterP1/2CCC (48)
Terelizumab
Colon Carcinoma
fan liP2CCC (48)
Tuvonralimab
Colon Carcinoma
Fujian Medical UniversityP2CCC (48)
Vebreltinib
Colon Carcinoma
Apollomics Inc.P2CCC (48)
Abemaciclib
Colon Carcinoma
M.D. Anderson Cancer CenterP1/2CC (46)
Cea-Targeted Car-T
Colon Carcinoma
Chongqing Precision Biotech Co., LtdP1/2CC (46)
Showing 51 to 100 of 154 assets
PreviousPage 2 of 4Next